Augtyro (repotrectinib) — Medica
Solid tumors (neurotrophic tyrosine receptor kinase [NTRK] gene fusion-positive)
Initial criteria
- Patient is age ≥ 12 years
- Tumor is positive for NTRK gene fusion
- Tumor is locally advanced or metastatic OR surgical resection of tumor will likely result in severe morbidity
Approval duration
1 year